Mechanistically, AP-2β inhibits 5-HTT expression [19, 20, 101] and inhibition of 5-HTT, by SSRIs for instance, leads to increased serotonin, which alleviates anxiety and depression [164]. Here, SLC6A4 is linked to major depressive disorder.